Albrecht, PBjørnå, KBrassat, DFarrell, RFeys, PHobart, JHupperts, RLinnebank, MMagdič, JOreja-Guevara, CPozzilli, CSalgado, AVZiemssen, T2018-11-202018-11-202018Ther Adv Neurol Disord. 2018 Oct 5;11:17562864188032481756-2864http://hdl.handle.net/10400.10/2056Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and re-treatment, and stopping criteria. This article summarizes the experts' opinions on how PR-fampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability.engMultiple sclerosisQuality of lifeFampridinejournal article10.1177/1756286418803248.